Immunochemical detection of urinary 5-methyl-2'-deoxycytidine as a potential biologic marker for leukemia.

A monoclonal antibody against 5-methylcytidine was prepared and characterized. This antibody, termed AMC, was reactive with compounds that had 5-methylcytosine structure (i.e. 5-methyl-2'-deoxycytidine, 5-methylcytidine and 5-methylcytosine). AMC had the highest reactivity to 5-methyl-2'-deoxycytidine among reactive compounds and had no or very slight cross-reactivity to cytidine-related compounds and any other compounds. Analysis of immunoreactive materials in urine revealed that 5-methyl-2'-deoxycytidine rather than 5-methylcytidine was, contrary to our expectation, the major component. Then the inhibition ELISA system using AMC was established and urinary levels of 5-methyl-2'-deoxycytidine in healthy individuals and cancer patients were determined. The mean excretion levels of healthy individuals was 0.90 +/- 0.43 nmol/mumol creatinine and the cut-off value was set at the mean + 2 S.D. of healthy individuals (1.76 nmol/mumol creatinine). Among various types of cancer tested, elevated levels of 5-methyl-2'-deoxycytidine were detected in leukemia patients. From these results, urinary 5-methyl-2'-deoxycytidine might be applicable as a biologic marker for leukemia.

[1]  K. Kuo,et al.  Patterns of urinary excretion of modified nucleosides. , 1979, Cancer research.

[2]  A. Niveleau,et al.  Monitoring of urinary excretion of modified nucleosides in cancer patients using a set of six monoclonal antibodies. , 1992, Cancer letters.

[3]  M. Mizugaki,et al.  Urinary excretion patterns of modified nucleosides, pseudouridine and 1-methyladenosine, in healthy individuals. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[4]  M. Mizugaki,et al.  Detection of elevated amounts of urinary pseudouridine in cancer patients by use of a monoclonal antibody. , 1989, Clinica chimica acta; international journal of clinical chemistry.

[5]  H. Topp,et al.  Possible use of urinary modified RNA metabolites in the measurement of RNA turnover in the human body. , 1986, Human nutrition. Clinical nutrition.

[6]  M. Ehrlich,et al.  Quantitative reversed-phase high-performance liquid chromatography of major and modified nucleosides in DNA. , 1984, Journal of chromatography.

[7]  J. Bertino,et al.  Methylation of nucleic acids in normal and leukemic leukocytes. , 1966, Biochimica et biophysica acta.

[8]  S. Belman,et al.  High turnover rate of transfer RNA in tumor tissue. , 1977, Cancer research.

[9]  S. Ishiwata,et al.  Relationship of urinary pseudouridine and 1-methyladenosine to activity of leukemia and lymphoma. , 1992, Clinica chimica acta; international journal of clinical chemistry.

[10]  B. Erlanger,et al.  ANTIBODIES SPECIFIC FOR RIBONUCLEOSIDES AND RIBONUCLEOTIDES AND THEIR REACTION WITH DNA. , 1964, Proceedings of the National Academy of Sciences of the United States of America.

[11]  T. Waalkes,et al.  New applications of urinary nucleoside markers. , 1983, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[12]  K. Kuo,et al.  Quantitative high-performance liquid chromatography of nucleosides in biological materials. , 1978, Journal of chromatography.

[13]  M. Mizugaki,et al.  Preparation of a Monoclonal Antibody Specific for 1‐Methyladenosine and Its Application for the Detection of Elevated Levels of 1‐Methyladenosine in Urines from Cancer Patients , 1988, Japanese journal of cancer research : Gann.

[14]  G. Rivard,et al.  Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. , 1985, Pharmacology & therapeutics.

[15]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[16]  S. Takano,et al.  Low molecular weight immunosuppressive factors found in elevated amounts in cancer ascitic fluids of mice. 2. 1-Methyladenosine isolated from cancer ascitic fluids enhances Listeria infection in mice. , 1986, Journal of immunopharmacology.